Stockscreener 앱 받기
0.62
7.83%
0.045
전일 마감가:
$0.575
열려 있는:
$0.58
하루 거래량:
81,453
Relative Volume:
0.55
시가총액:
$36.17M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
62.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
-4.17%
1개월 성능:
+5.10%
6개월 성능:
-53.03%
1년 성능:
-63.31%
1일 변동 폭
$0.57
$0.6421
1주일 범위
$0.57
$0.668
52주 변동 폭
$0.5052
$1.72
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
0.62 | 36.17M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times
Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune
Spero Therapeutics Confirms Q1 Earnings Date: Latest Updates on Rare Disease and MDR Programs Coming May 13 - Stock Titan
Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz
New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus
Spero Therapeutics appoints new CEO and board nominee - Investing.com
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire
Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com
Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener
Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: - GuruFocus
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
Spero Therapeutics earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Spero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Q4 Earnings: $68.6M Loss, Pipeline Setbacks, and New Interim CEO Named - Stock Titan
A Glimpse of Spero Therapeutics's Earnings Potential - Benzinga
Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Spero Therapeutics Q4 Earnings: Rare Disease Pipeline and Financial Results Coming March 27 - StockTitan
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - The AM Reporter
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com Australia
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday - The AM Reporter
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Spero Therapeutics Inc 주식 (SPRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rajavelu Esther | CFO & CBO |
Feb 05 '25 |
Sale |
0.78 |
20,689 |
16,137 |
724,720 |
| Shukla Sath | CEO & President |
Feb 05 '25 |
Sale |
0.78 |
155,333 |
121,160 |
1,736,883 |
| Mahadevia Ankit | Director |
Feb 05 '25 |
Sale |
0.78 |
69,219 |
53,991 |
689,866 |
| Rajavelu Esther | CFO & CBO |
Nov 07 '24 |
Sale |
1.31 |
23,351 |
30,590 |
396,515 |
| Rajavelu Esther | CFO & CBO |
Nov 08 '24 |
Sale |
1.30 |
17,245 |
22,418 |
379,270 |
| Mahadevia Ankit | Director |
Aug 27 '24 |
Sale |
1.35 |
5,912 |
7,981 |
759,085 |
| Keutzer Timothy | Chief Operating Officer |
Aug 27 '24 |
Sale |
1.35 |
2,213 |
2,988 |
531,837 |
| Shukla Sath | CEO & President |
Aug 27 '24 |
Sale |
1.35 |
2,757 |
3,722 |
1,140,809 |
| Shukla Sath | CEO and President |
Aug 05 '24 |
Sale |
1.31 |
17,641 |
23,110 |
1,143,566 |
| Shukla Sath | CEO and President |
Aug 02 '24 |
Sale |
1.32 |
14,800 |
19,536 |
1,161,207 |
0.84%
0.15%
자본화:
|
볼륨(24시간):